Radionuclide-labeled HER2-targeting antibody (investigational)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Radionuclide-labeled HER2-targeting antibody (investigational), covering 2025-06-17 to 2025-06-17. Get the full timeline:
Most recent: Clinical Trial Update: The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies [EARLY_Phase 1]